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The B-13 cell is a readily expandable rat pancreatic acinar-like cell that differentiates on simple plastic culture substrata into replicatively-senescent hepatocyte-like (B-13/H) cells in response to glucocorticoid exposure. B-13/H cells express a variety of liver-enriched and liver-specific genes, many at levels similar to hepatocytes in vivo. Furthermore, the B-13/H phenotype is maintained for at least several weeks in vitro, in contrast to normal hepatocytes which rapidly de-differentiate under the same simple -or even under more complex -culture conditions. The origin of the B-13 cell line and the current state of knowledge regarding differentiation to B-13/H cells are presented, followed by a review of recent advances in the use of B-13/H cells in a variety of toxicity endpoints. B-13 cells therefore offer Toxicologists a cost-effective and easy to use system to study a range of toxicologically -related questions. Dissecting the mechanism(s) regulating the formation of B -13/H cell may also increase the likelihood of engineering a human equivalent, providing Toxicologists with an expandable donor-free supply of functional rat and human hepatocytes, invaluable additions to the tool kit of in vitro toxicity tests.
Origin of the B-13 cell line
The AR42J-B13 (henceforth referred to as the B-13) cell line was sub-cloned from the rat adenocarcinoma AR42J cell line in the late 1970s. The AR42J cell line is an exocrine pancreatic adenocarcinoma cell line still used to the present day in basic exocrine pancreas research. [1] [2] [3] [4] [5] [6] The AR42J cell line was derived from studies in which inbred Wistar/Lewis rats were treated with azaserine (O-diazoacetyl-L-serine). 7 Azaserine is a naturally occurring antibiotic first isolated from Streptomyces fragilis 8 that causes cytotoxicity in cells through at least 2 mechanisms:-inhibition of N-formylglycineamidine ribotide synthetase (PFAS, phosphoribosylformylglycinamidine synthase), which results in an inhibition of purine biosynthesis; 9 and through spontaneous decomposition to yield diazoacetate, which carboxymethylates DNA primarily on the O6 and N7 of guanine and the N3 of adenine. [10] [11] [12] Azaserine is also an inhibitor of glucosamine-6-phosphate isomerase (GFPT1) 9 and is often used experimentally in studies on hexosamine biosynthesis. 13 A single intraperitoneal injection of 30 mg azaserine/kg body weight is capable of inducing adenoma and subsequently carcinoma in rats several months after exposure, primarily in the pancreas.
14 Accordingly, azaserine has been used in the past to generate experimental models of pancreatic cancer. [15] [16] [17] [18] [19] Why the pancreas is a target organ for tumours with azaserine however, remains unclear.
AR42J cells were isolated from tumour cells generated from the rat azaserine studies of Longnecker et al 7 and were transplanted back into untreated rats of the same strain by subcutaneous and intraperitoneal injections up to five times. The transplanted cells were reported to be capable of forming tumours at the site of injection and in lung and liver in some recipients. 7 The AR42J cell line generated was noted to express high levels of amylase and other pancreatic exocrine enzymes. 20 For summary, see Fig. 1 . The B-13 cell line was sub-cloned from the AR42J cell line by the Kojima lab in 1996 and was reported to differentiate into insulin-producing pancreatic endocrine β-like cells in vitro after treatment with hepatocyte growth factor (HGF) and activin A.
The B-13 cell line readily proliferates in simple cell culture media such as Dulbecco's modified Eagle medium (DMEM) supplemented with serum (typically 10% (v/v)), with a doubling time of 30 +/-7.3 hours. 46 The cells do not require any of the culture modifications often associated with stem cell maintenance (such as fibroblast feeders, matrigel or colony selection during sub-culture to select for progenitor characteristics). The cells will readily expand on plastic substrata and appear to have an altered -but stable -near tetraploid karyotype of male origin. 27 It is unknown for how long this karyotype has been stable, however B-13 cells have been repeatedly trans-differentiated into B-13/H cells for last 15 years, suggesting alterations at the genomic DNA level are very stable. B-13 cells do not grow in agar in vitro, and do not readily form tumours in SCID mice. However, B-13 cells are capable of selectively engrafting into the pancreas and liver after intravenous injection, and spontaneously forming hepatocyte-like cells in the liver.
27 B-13 cells therefore appear to retain some of the pathways that restrain dysregulated cell growth and differentiation. Were it not for their unique ability to differentiate into hepatocyte-like cells, B-13 cells might be considered no different from any other cell line.
The liver and pancreas are thought to contain progenitor cells localised in the ductal regions of the tissue (Fig. 2) . Using the neural marker synaptophysin -which is expressed by B-13 cells and suppressed in B-13/H cells, 26 it is possible to identify putative progenitors in a limited number of both rat liver and pancreas ductal regions. The study of these progenitor cells in vitro is challenging since, in contrast to B-13 cells, the progenitor cells are difficult to purify and maintain as a pure population of progenitors. In the rat, liver progenitors (oval cells) are bi-potential and give rise to hepatocytes and biliary epithelial cells (cholangiocytes) in vivo. 85, 86 In our hands, rat oval cells in culture rapidly generate biliary epithelial cells and/or fibroblasts (possibly through epithelial-mesenchymal trans-differentiation of biliary epithelial cells) and form a minority of the cell population within a day or two of isolation (Fig. 3) .
The data to date suggest that the B-13 may be equivalent to a pancreatic or liver progenitor cell since it trans-differentiates from the B-13 acinar phenotype directly to the hepatocyte-like B-13/H phenotype. Using a B-13 cell line stably transfected with a green fluorescent protein (GFP) gene under control of a promoter (which is trans-activated in exocrine pancreas cells) Shen et al 23 showed that after exposure to glucocorticoid, cells could be identified that expressed both GFP and hepatocyte markers, suggesting that the mechanism of altered differentiation is likely a direct conversion from its "differentiated" pancreatic exocrine cell type directly to an hepatocyte, without reverting to a plastic progenitor-like intermediate).
However, more recently, limited evidence suggests that B-13 cells may be directed to form a ductal (i.e. biliary-like) phenotype in response to glucocorticoid and EGF. 87 However, the identity of these cells is ambiguous, likely because the response lacks the quantitative transdifferentiation response seen with B-13/H cells and hepatocytes. This apparent plastic nature of B-13 cells may be reflective of the type of responses seen in a variety of cells in vitro, such as epithelial-mesenchymal transition (EMT), which commonly occur in vitro. 88, 89 However, whether B-13 cells enter (or are capable under certain circumstances of entering) a transient plastic state prior to conversion to B-13/H cells remains uncertain.
Mechanism(s) mediating the formation of B-13/H cells
There is good evidence to suggest that the glucocorticoid receptor (GR) mediates the response to glucocorticoid in B-13 cells and initiates the process of trans-differentiation. The synthetic glucocorticoid dexamethasone is frequently employed in generating B-13/H cells because it is less rapidly metabolised than natural glucocorticoids and is more selective for the GR than many natural glucocorticoids. 29, 30 However, B-13 cells respond similarly to a range other glucocorticoids and the response is inhibited by GR antagonists. 23, 90 Other classes of steroids (e.g. oestrogens) fail to promote the transdifferentiation of B-13 cells into B-13/H cells 90 (see also Fig. 4 ) and although glucocorticoids also activate the mineralocorticoid receptor, 91 B-13 trans-differentiation to B-13/H cell does not occur in response to mineralocorticoids, nor is glucocorticoiddependent trans-differentiation blocked by mineralocorticoid receptor antagonists. 92 Previous studies over the years have reported the appearance of hepatocyte-like tissue in pancreatic exocrine tissue in vivo, in response to a variety of pathological conditions (Table 4 ). More recent observations have focussed on the effects of glucocorticoid on pancreatic exocrine tissue differentiation. These studies have shown that both rodent and human embryonic acinar cells can be converted into hepatocyte-like cells in response to glucocorticoid in vitro. 109, 110 However, of fundamental importance from a practical point of view, the quantitative functionality of these pancreatic hepatocyte-like cells to hepatocytes from the liver was rarely made. When such comparisons were made, on a quantitative basis, it is arguable whether such cells could be defined as hepatocytes. However, this lack of quantitative comparability may be a feature of the in vitro environment in which the cells were cultured, and does not indicate necessarily that the cells were not capable of forming functional hepatocytes in the correct environment (such as in vivo). This is supported by recent studies in both rodents and man. 24, 90 Using in vivo models, Wallace et al demonstrated that treatment with high doses of glucocorticoid to adult rats for just a few weeks is enough to convert occasional pancreatic acinar cells into cells that express liver-levels of CYP2E1.
24
In a transgenic mouse with high circulating endogenous circulating glucocorticoids and which showed many of the clinical features of Cushing's disease, significant liver-levels of hepatocyte gene expression could be observed in the pancreata of many mice by adulthood (21 weeks of age). 107 The normal pancreas is therefore capable of altering to an hepatocyte-like phenotype that shows comparable levels of hepatocyte gene expression in vivo when exposed to pathologically high levels of glucocorticoid. Interestingly, these data also show that such a phenomenon is not restricted to embryonic or foetal tissue. Recent investigations also indicate that pancreata from adult patients maintained on high levels of systemic glucocorticoid therapy also express hepatocyte levels of hepatocyte expressed genes, 90 suggesting that the observations in rodents are likely translatable to man.
Although it was clear from the first observations by Shen et al that the liver-enriched transcription factor CCAAT/enhancerbinding protein-β (CEBP-β) was a pivotal downstream mediator of B-13 trans-differentiation to B-13/H cells, 23 the signalling pathways that lead from glucocorticoid to the induction of this transcription factor in B-13 cells are only recently being determined. Wallace et al provide strong evidence to suggest that GR activation in B-13 cells leads to a robust induction of the serine/threonine kinase SGK1 92 and that this kinase, at least in part, phosphorylates the Wnt signalling protein messenger β-catenin as a component of the mechanism that precedes induction of transcription factors such as CEBP-β (see also Fig. 5c for schematic diagram of proposed proximal mechanism of trans-differentiation). 48, 29 The physiological function of SGK1 in vivo is in the regulation of sodium salt re-absorption by the kidney. The kinase functions to mediate mineralocorticoid stimulation of renal sodium channel (ENaC) activity and anti-natriuresis through its phosphorylation of the ubiquitin ligase Nedd4-2, which leads to a block in epithelial ENaC ubiquitylation, a reduction in ENaC endocytosis and increased renal tubular epithelial sodium transport into the cell.
111 SGK1 mediates a stress response to low salt levels, promoting salt re-absorption. Accordingly, knockout of the Sgk1 gene in mice has no overt effect on mice unless the mice are forced onto a low salt intake. 112, 113 To date, a role for SGK1 in cell differentiation and/or tissue development -with the exception of B-13 cellshas not been identified. However, a limited microarray study that compared the levels of approximately 5000 transcripts in B-13 and B-13/H cells identified SGK1 as the highest induced transcript in response to glucocorticoid treatment [supplementary data to Wallace et al 24 ] . Subsequent studies demonstrated that expression of either of 2 human SGK1 variants (but not the "wild type" variant A) alone, drove B-13 trans-differentiation into B-13/H cells (see also Fig. 5 ). 92 The SGK1 variants are identical with the exception of alternative Nterminal domains.
These differentiation-promoting SGK1 variants are also induced in both mouse and human pancreatic acinar hepatic tissue or cells after exposure to high glucocorticoid. 107, 90 Using recombinant SGK1 and β-catenin, it was shown that SGK1 was able to phosphorylate β-catenin on the residues that target β-catenin for ubiquitination and degradation, 92 a process that would be expected to downregulate the Wnt signalling pathway. A Wnt signallingresponsive promoter-reporter gene construct suggested that Wnt signalling activity was highly active in B-13 cells. 48 Inhibition of Wnt signalling (using the inhibitor quercetin or through over-expression of a mutant β-catenin [pt-Xβ-cat]) or siRNA to knockdown β-catenin expression) alone resulted in Cebp-β induction and trans-differentiation of B-13 cells into B-13/H cells. 48 It is likely therefore, that specific Sgk1 variants provide the link between GR activation and the Wnt signalling pathway, and that this crosstalk lies upstream of Cebp-β induction and trans-differentiation. In normal cells, this cross talk is unlikely to be operational and is only relevant in pathological situations such as chronic hyper-elevated glucocorticoid levels. However, the Sgk1 cross talk with Wnt signalling may be amplified in some way in B-13 cells (e.g. through an over-induction and/or sustained elevation in SGK1 expression and/or a constitutively active PI3 kinase signalling pathway) such that the crosstalk mechanism is responsive in B-13 cells at physiologically normal concentrations of glucocorticoid.
Notable features of B-13/H cell formation
There are several features of the trans-differentiation of B-13 cells into B-13/H cells that are striking, particularly in the context of current attempts to generate functional hepatocytes from embryonic stem cells or induced pluripotent stem cells for use in hepatology or toxicology research.
Treatment with glucocorticoid is sufficient to promote the trans-differentiation of B-13 cells into B-13/H cells.
This contrasts markedly with the range of different growth factors and other poorly defined additions (e.g. matrigel, fibroblast feeder layers) that are required or often used when ESCs or iPSCs are directed to differentiate into hepatocyte-like cells in vitro. Recombinant growth factors are also relatively expensive to produce and purify and are subject to variable functional activity, whereas glucocorticoids are inexpensive and relatively simple, stable chemicals.
A major physiological function of glucocorticoids is as a regulator of general metabolism.
Glucocorticoids are synthesised by the adrenals and the levels secreted into the blood are controlled by the hypothalamus-pituitary-adrenal (HPA) axis. diuresis and have a general immunosuppressive (most notably, anti-inflammatory) effect, a feature that is often employed for therapeutic reasons. 115 However, glucocorticoids also have a developmental role, at least within the foetus. Circulating levels of glucocorticoid are low in the embryo and foetus (placental enzymes such as 11β-hydroxysteroid dehydrogenase [HSD2] metabolise glucocorticoids to inactive products and foetal levels only rise as the foetal HPA axis develops). 116, 140 This rise in circulating foetal glucocorticoid probably plays a major role in cell differentiation and tissue maturation, most notably in the lung, since premature babies are successfully treated with glucocorticoids to promote lung maturation.
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A biologically relevant GR activating concentration of glucocorticoids (typically 10 -8 M) is sufficient to promote the trans-differentiation of B-13 cells into B-13/H cells. The affinity of the rat GR for dexamethasone is in the 10 -9 M range (KD = 2.3nM 118 ) and typically, 10 -8 M dexamethasone is employed to robustly activate the GR in cells in vitro. The GR is expressed in B-13 cells, is transcriptionally functional and its activity and apparent ability to drive B-13/H formation at 10nM dexamethasone is blocked by GR antagonists. 90, 119 In primary pancreatic rodent and human acinar cell cultures, significantly higher (10 -6 to 10 -5 M) concentrations are required (and produce a quantitatively much reduced trans-differentiation to hepatocyte-like phenotype). 87, 90 The reason(s) for this are unclear.
Although there is another receptor protein for dexamethasone in the rat with a lower affinity for dexamethasone (KD = 59nM 118 ), the antagonist RU486 does not block dexamethasone binding to this protein, whereas RU486 blocks primary pancreatic rodent and human acinar cell transdifferentiation to hepatocyte-like cells.
23, 92 These observations therefore suggest that the activated GR may be hyper-functional in B-13 cells, although the reason(s) for this remain to be elucidated.
Exposure of B-13 cells to glucocorticoid converts the majority of the cells into a non-replicative B-13/H phenotype, with often less that 5% of the cells remaining in a B-13 phenotype. From a practical point of view, a striking feature of hepatocyte-like cell generation from B-13 cells is the near complete trans-differentiation of B-13 cells to B-13/H cells in response to glucocorticoid. It is therefore possible to generate a near pure population of hepatocyte-like cells with relative ease. This contrasts with the potential for ESCs and iPSCs to differentiate into a variety of cells, although protocols are beginning to address this problem and hepatocyte purity has increased from early reports.
Although the liver has the capacity to regenerate in vivo through mitosis of existing hepatocytes in vivo, hepatocytes in culture do not readily undergo mitosis in vitro. 119 Through additions of growth factors, low seeding densities etc, it is possible to stimulate DNA synthesis in cultured hepatocytes, but hepatocytes rarely complete the cell cycle in vitro and therefore, the cells are not readily expanded in vitro in the way that replicative cells lines may be expanded. 119, 120 In this respect, it is possible that the de-differentiation of hepatocytes when they are cultured under conditions designed to promote growth, has the effect of pushing them into the cell cycle from which they cannot emerge. 121 In contrast, avoiding this regenerative-like response through culturing cells in sandwich cultures of extracellular matrix and/or 3D matrices may explain their superiority in maintaining hepatic function in culture [51] [52] [53] . [122] [123] [124] B-13 cells are resistant to differentiation into other cell types in response to typical differentiating factors such as soluble growth factors and cytokines. In the liver, the progenitor cell (termed oval cell in rodents) is bi-potential and capable of differentiating into either hepatocytes or biliary epithelial cells. 85, 86 It is thought that oval cells only give rise to significant numbers of hepatocytes in liver regeneration when hepatocytes are prevented from undergoing mitosis themselves. 85, 86 If the B-13 cell is derived or markedly related in function to a pancreatic/hepatic progenitor, then one might expect that the B-13 cell be capable of differentiating into other pancreatic and/or hepatic cell types.
B-13 cells have been directed toward a pancreatic β cell phenotype although there appears to be a requirement for ectopic over-expression of specific transcription factors.
21,22,125
Treating B-13 cells with glucocorticoid and then EGF also promotes a ductal-like phenotype. 87 Since it is arguably the case that many cell types can be forced to alter their phenotype into other cell types if the appropriate transcription factors are over-expressed (often referred to as direct lineage conversion 126 :-the induction of pluripotency by c-Myc, Klf4, Oct4 and Sox2 127,128 being effectively direct linear conversion to pluripotent stem cells / indirect linage conversion to other mature cells), then it may not be surprising that B-13 cells can be directed into phenotypes other than hepatocytes when given the required non-hormonal signals, if sufficiently potent. However, in all cases so far, the quantitative comparable functional differentiation of B-13 cells into other cell types in response to hormonal factors alone, does not compare with the robust response seen with respect to glucocorticoid and hepatocytelike cell formation. Thus, B-13 cells resist differentiation into other cell types in response to typical differentiating factors such as soluble growth factors and cytokines. B-13/H cells are quantitatively similarly functional to freshly isolated rat hepatocytes. As outlined above, a marked feature of B-13/H formation from B-13 cells is their quantitative comparability to primary rat hepatocytes. This feature is relevant in particular, when considering in vitro cell models for studying toxicity mechanisms and potentially using the model to screen for drug and chemical toxicity.
Most chemical toxicities (both cytotoxic and genotoxic) in man are the result of metabolic activation in a target tissue(s) because exposure to directly cytotoxic reactive chemicals are normally avoided. 129 A major driver of activation pathways is the level of expression of gene products associated with protoxin activation. In simplistic terms, expression of genes associated with metabolic activation are required to be expressed at levels at least approximating to those found in the target organ(s) for the cells to be a realistic in vitro model for toxicity assessment. This remains only an initial requirement since, additional layers of complexity would need to be taken into account (e.g. toxicokinetics, protective pathways etc) before such in vitro models could be used to predict in vivo toxicity.
Conclusions
The B-13 cell line provides an expandable donor-free supply of functional rat hepatocyte-like cells that can be readily used without a requirement for expertise found outside the average toxicology laboratory. There remain some limitations to B-13/H cells, such as the fact that they are rat cells and not human, and that there are limitations in the expression of some transporters such as NTCP. However, given their ease of use and cost effectiveness, on balance B-13 cells have clear value in toxicity testing. Loss of some genes, such as CYP1A2, can be overcome through ectopic expression (e.g. the human gene 45, 26 Essential for functional microsomal cytochrome P450 activity. 49 Required for toxic effects of many drugs and chemicals. 129 Total CYP450 SPEC 45, 27 Major xenobiotic metabolising gene superfamily. 50 Reduced CO versus reduced spectra peak at 450nm. It is possible to generate cells with similar levels to rat hepatocytes detectable. 27 Required for toxic effects of many drugs and chemicals. 129 Cytochrome b5 SPEC Unpublished.
Aryl hydrocarbon receptor (AhR)
RT-PCR 46 Receptor for polyaromatic hydrocarbon xenobiotics -regulates induction of CYP1 genes. 51 Aryl hydrocarbon receptor nuclear translocator (AhRNT)
RT-PCR 46 Heterodimerizes with AhR , essential for effective AhR-mediated transcriptional function.
CYP1A1
RT-PCR, 46 WB, 46 FUNC 46 .
Expression induced by AhR activator β-naphthoflavone. 46 See also Fig. 6 . Required to generate genotoxic products from many polyaromatic hydrocarbons such as benz(α)pyrene.
46

CYP1A2
Absent -RT-PCR, 46 absent -WB, 46 absent -FUNC 46 All alleles appear disrupted in cell line. 46 Expression of human CYP1A2 mediates PhIP activation to a genotoxic product. 46 
Constitutive androstane receptor (CAR)
RT-PCR 46 Transcriptional regulator of CYP2B induction response .
52
CYP2B1
RT-PCR, 46 absent -WB, 46 present WB, 26 ICC, 28 absent -FUNC 46 CAR activators result in induction in mRNA expression, but translation is lacking. 46 See also Fig. 6 . Note, CYP2B1 is not constitutively significantly expressed in rat hepatocytes, only after administration of inducers .
53
CYP2B2
Absent -RT-PCR, 46 CYP2C11 is the major (male-specific) adult hepatic cytochrome P450. Expression is liver-specific. 55 Metabolises methapyrilene to an hepatotoxic product, 141 also observed in B-13/H, but not in B-13 cells.
CYP2C12 is the major (female-specific) adult hepatic cytochrome P450, Expression is liver-specific. 55 Levels of mRNA in B-13/H cells are less than 1% of the levels seen in female rat liver.
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CYP2C13
RT-PCR 47 Male-specific isoform, specific to liver. Basolateral-localised transporter, possibly mediates transport of cyclic nucleotides such as cGMP 74 although this has been questioned. 73, 75 Higher mRNA levels in B-13/H than intact rat liver.
46
Abcc6 (MRP6) RT-PCR, 46 FUNC 46 Basolateral-localised transporter, predominantly expressed in the plasma membrane of the hepatocyte (and to a lesser extent in the kidney). 76 Mutations in the gene cause a rare, recessive genetic disease, pseudoxanthoma elasticum. 76 Similar mRNA levels in B-13/H to intact rat liver. Basolateral -localised transporter, mediates uptake of organic cations. 81 Expressed at high levels in kidney. 81 Similar mRNA levels in B-13/H to intact rat liver. Expressed predominantly in the kidneys and localized exclusively to the basolateral membrane of proximal tubular cells. Mediates the uptake of various small, negatively charged molecules, such as endogenous metabolites, toxicants, and numerous clinically used therapeutics -functions as an antiporter exchanging intracellular α-ketoglutarate against extracellular organic anions and drugs. 82 Similar mRNA levels in B-13/H to intact rat liver. 46 This journal is © The Royal Society of Chemistry 2012 J. Name., 2012, 00, 1-3 | 15
Expressed in liver and kidney. Apical renal transporter in rat. 82 It is unclear why OAT2 in humans and Oat2 in rodents show a basolateral versus apical localization in proximal tubules. The presumed localization of OAT2/Oat2 in the sinusoidal membrane of hepatocytes awaits an experimental proof . Putative progenitor cells were isolated from pronase digestion of the bilary tree remaining after a two-step collagenase digestion of rat liver 131 A, Light micropgraphs (upper panels) of cell types observed after 3 days of culture. Lower panels, immunocytochemical staining for progenitor (OV-6), ductal (CK-19 and fibroblast (vimentin) markers 129 in the morphologically distinct cell types after 3 days of culture, stained essentially as described . 48 B, RT-PCR analysis for the indicated transcript essentially as described.
24,48
Figure 4. Oestrogens do not affect B-13 cell differentiation via the ER or GR. Recent work has demonstrated that B-13 cells are capable of differentiating into ductal-like cells 87 and that an alternative nuclear receptor -the oestrogen receptor-α (ERα) -mediates the effects of glucocorticoids in lumen-forming cells (such as the progenitor cells of the liver, which are bi-potential and capable of forming hepatocytes or the lumen-forming cholangiocytes). 132 A, demonstrates that the mRNA for ERα as well as the related ER gene ERβ are not detectable in B-13 cells in contrast to rat hepatocytes (which are known to express ERα 133 ) and uterus and the ovary (which has previously been reported to express the ERβ 134 ). RT-PCR analysis for the expression of ERα and ERβ mRNA transcripts in 4 separate B-13 cell cultures, after 30 cycles essentially as described.
24,48 B, transfection of an oestrogen receptor-responsive reporter gene construct (ERE3-pGL3promoter) 135 into B-13 cells and treatment with either DEX or the natural endogenous oestrogen receptor activating ligand 17β oestradiol (E2) resulted in significant ERE3-pGL3promoter reporter gene expression in response to DEX * . However, only the GR antagonist RU486 -and not two oestrogen receptor antagonists (tamoxifen or ICI182780) significantly inhibited DEXdependent increases in ERE3-pGL3promoter reporter gene expression $ . These data therefore suggest that DEXdependent activation of the GR is responsible for the increase in ERE3-pGL3promoter reporter gene expression, likely due to high GR expression in B-13 cells. This is supported by alterations in phenotype (C) or expression of hepatic markers (D) as determined by Western blotting.
Figure 5. Over-expression of SGK1F induces a trans-differentiation of B-13 cells to B-13/H cells without the addition of glucocorticoid. B-13 cells were infected with an adenovirus encoding the human SGK1F isoform (AdV-SGK1F) which has been previously shown to direct B-13 differentiation into B-13/H cell, 92 or a control adenovirus encoding NTCP (AdV-control) and morphology examined after 3 days (A) or cells harvested at day 5 for Western blotting (B) for the indicated protein.
24, 48 Where indicated, cells were also treated with dexamethasone (DEX), the GR antagonist RU486 or the SGK1 antagonist GSK 650394 (GSK). 136 For more details on variant SGK1 isoforms and methodology, see Wallace et al, including supplementary data.
92 C, Schematic diagram illustrating the cross talk between the GR, SGK1 and WNT signalling pathways operating in B-13 cells. 137 essentially as previously described. 46 The cells were then counterstained with DAPI. Cells were photographed using a Zeiss fluorescence microscope and staining quantified using ImageJ particle counter. Results were normalised to cell number. Results are the mean and SD of 5 fields of view from the same experiment, typical of at least 3 separate experiments. Scale bar indicates 48μm. *significantly different to vehicle control at p<0.05.
